Patents by Inventor Peter-Colin Gregory
Peter-Colin Gregory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190275122Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.Type: ApplicationFiled: May 23, 2019Publication date: September 12, 2019Inventors: George Shlieout, Bernd Boedecker, Siegfried Schaefer, Bernd Thumbeck, Peter-Colin Gregory
-
Patent number: 9539311Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: GrantFiled: April 6, 2015Date of Patent: January 10, 2017Assignees: Novozymes A/S, Novozymes Inc.Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Publication number: 20150209414Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: ApplicationFiled: April 6, 2015Publication date: July 30, 2015Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Patent number: 9029115Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: GrantFiled: August 16, 2012Date of Patent: May 12, 2015Assignees: Novozymes A/S, Novozymes IncInventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Publication number: 20140302000Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.Type: ApplicationFiled: June 18, 2014Publication date: October 9, 2014Inventors: George Shlieout, Bernd Boedecker, Siegfried Schaefer, Bernd Thumbeck, Peter-Colin Gregory
-
Patent number: 8802087Abstract: Orally administrable pharmaceutical compositions of lipase-containing products, particularly pancreatin and pancreatin-containing products, or of enzyme products which contain at least one lipase of non-animal, especially microbial origin, which improve the lipolytic activity and particularly result in stabilization of the lipase in the acidic pH range. These oral pharmaceutical compositions contain a system which includes at least one surfactant and one co-surfactant and optionally a lipophilic phase, and are self-emulsifiable on contact with a hydrophilic and a lipophilic phase. The compositions according to the invention are suitable for treating or inhibiting maldigestion, especially maldigestion due to chronic exocrine pancreatic insufficiency, in mammals and humans.Type: GrantFiled: March 22, 2005Date of Patent: August 12, 2014Assignee: Abbott Products GmbHInventors: George Shlieout, Bernd Boedecker, Siegfried Schaefer, Bernd Thumbeck, Peter-Colin Gregory
-
Patent number: 8455235Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: GrantFiled: December 2, 2008Date of Patent: June 4, 2013Assignees: Novozymes A/S, Solvay Pharmaceuticals, GmbHInventors: Allan Svendsen, Lars Beier, Signe Eskildsen Larsen, Thomas Lenhard, Tanja Maria Rosenkilde Kjaer, Peter Colin Gregory
-
Publication number: 20120308543Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: ApplicationFiled: August 16, 2012Publication date: December 6, 2012Applicants: NOVOZYMES, INC., NOVOZYMES A/SInventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Patent number: 8273348Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: GrantFiled: December 12, 2007Date of Patent: September 25, 2012Assignees: Novozymes A/S, Novozymes Inc.Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Publication number: 20120207741Abstract: The pharmaceutical use of proteases related to a protease derived from Nocardiopsis sp. NRRL 18262 (SEQ ID NO: 1), optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: April 26, 2012Publication date: August 16, 2012Applicant: NOVOZYMES A/SInventors: Allan Svendsen, Svend Kaasgaard, Kim Borch, Morten Fischer, Dan Pettersson, Peter Colin Gregory
-
Patent number: 8058264Abstract: Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one KATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB1 antagonistic properties is used.Type: GrantFiled: October 25, 2005Date of Patent: November 15, 2011Assignee: Abbott Products GmbHInventors: Michael Firnges, Peter-Colin Gregory, Jochen Antel, Josephus Hubertus Maria Lange, Harald Waldeck
-
Publication number: 20110158976Abstract: The pharmaceutical use of proteases related to a protease derived from Nocardiopsis sp. NRRL 18262 (SEQ ID NO: 1), optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: May 24, 2005Publication date: June 30, 2011Applicant: NOVOZYMES A/SInventors: Allan Svendsen, Svend Kaasgaard, Kim Borch, Morten Fischer, Dan Pettersson, Peter Colin Gregory
-
Publication number: 20110110910Abstract: The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: January 19, 2011Publication date: May 12, 2011Applicants: Novozymes A/S, Solvay Pharmaceuticals GmbHInventors: Allan Svendsen, Claus Crone Fuglsang, Peter Colin Gregory
-
Publication number: 20100322915Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: December 2, 2008Publication date: December 23, 2010Applicants: Novozymes A/S, Solvay Pharmaceuticals, GmbHInventors: Allan Svendsen, Lars Beier, Signe Eskildsen Larsen, Thomas Lenhard, Tanja Maria Rosenkilde Kjaer, Peter Colin Gregory
-
Patent number: 7772225Abstract: The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.Type: GrantFiled: December 8, 2006Date of Patent: August 10, 2010Assignee: Solvay Pharmaceuticals GmbHInventors: Jochen Antel, Michael Firnges, Uwe Schoen, Harald Waldeck, Michael Wurl, Dania Reiche, Peter-Colin Gregory
-
Patent number: 7763607Abstract: Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a KATP channel modulator; and (ii) a CBx modulator. Also described herein are methods of making and using these compositions.Type: GrantFiled: April 26, 2007Date of Patent: July 27, 2010Assignee: Solvay Pharmaceuticals GmbHInventors: Jochen Antel, Peter-Colin Gregory, Josephus Hubertus Maria Lange, Michael Firnges, Dania Reiche
-
Publication number: 20100135978Abstract: The pharmaceutical use of proteases related to amino acids 1-274 of SEQ ID NO: 2, the serine protease derived from Bacillus licheniformis, which is also designated subtilisin Carlsberg, optionally in combination with a lipase and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.Type: ApplicationFiled: January 26, 2010Publication date: June 3, 2010Applicants: Novozymes A/S, Solvay Pharmaceuticals GmbHInventors: Allan Svendsen, Claus Crone Fuglsang, Peter Colin Gregory
-
Publication number: 20100034797Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.Type: ApplicationFiled: December 12, 2007Publication date: February 11, 2010Applicants: Novozymes A/S, Novozymes, Inc., Solvay Pharmaceuticals GmbHInventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehman Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
-
Patent number: 7547708Abstract: N-sulfamoyl-N?-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditionsType: GrantFiled: November 14, 2006Date of Patent: June 16, 2009Assignee: Solvay Pharmaceuticals, Inc.Inventors: Jochen Antel, Harald Waldeck, Uwe Schoen, Peter-Colin Gregory, Michael Wurl, Michael Firnges, Dania Reiche, Uwe Reinecker, Holger Sann
-
Publication number: 20090104126Abstract: A sulfamate compound corresponding to Formula I wherein R1 to R3 and n have defined meanings, pharmaceutical compositions comprising these compounds; a process for preparing these compounds, and the use of such compounds or compositions to treat or inhibit various disorders or disease states in patients in need thereof by administering to such a patient a therapeutically effective amount of such a compound.Type: ApplicationFiled: October 17, 2008Publication date: April 23, 2009Applicant: Solvay Pharmaceuticals GmbHInventors: Uwe SCHOEN, Harald Waldeck, Uwe Reinecker, Peter-Colin Gregory, Dania Reiche, Holger Sann, Michael Wurl, Jochen Antel